“The existing problem has uncovered some structural weaknesses in the EU’s medicines supply chain in addition to a large dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides mentioned. She recommended that provide chain concerns be tackled in an EU pharmaceutical tactic predicted being released by the top from the y